Content in this video provided updates and cutting-edge insight on novel artificial intelligence (AI), clinical trial designs and innovative strategies, safety data in clinical trials, combination products, electronic submissions and more. Subject matter experts provided insight on FDA’s perspectives, adoption of regulatory guidelines, opportunities for stakeholders to engage with CDER and best practices.
Timestamps
00:50 – Electronic Submission Gateway (ESG) Modernization: ESG NextGen
31:34 – Q&A Session
41:25 – Artificial Intelligence (AI) | Machine Learning (ML): The New Frontier of Drug Development and Regulation
01:10:19 – Q&A Session
Speakers:
Jessica Bernhardt, MS
ESG Program Manager
Division of Application Services (DAS)
Enterprise Application Branch (EAB)
Office of Digital Transformation (ODT)
Office of Information Management and Technology (OIMT) | FDA
Bin Duan
ESG NextGen Lead Architect CTO
Precise Software Solutions Inc.
Qi Liu, PhD, MStat, FCP
Associate Director for Innovation & Partnership
Office of Clinical Pharmacology (OCP)
Office of Translational Sciences (OTS)
Center for drug Evaluation and Research (CDER) | FDA
———————–
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
Upcoming Training - https://www.fda.gov/cdersbia
SBIA Listserv – https://public.govdelivery.com/accounts/USFDA/subscriber/new?topic_id=USFDA_352
SBIA 2024 Playlist – https://www.youtube.com/playlist?list=PLey4Qe-Uxcxaf1HvpvnKO8-n8u9QW412g
SBIA LinkedIn - https://www.linkedin.com/showcase/cder-small-business-and-industry-assistance
SBIA Training Resources - https://www.fda.gov/cdersbialearn
Twitter - https://twitter.com/FDA_Drug_Info
Email - CDERSBIA@fda.hhs.gov
Phone - (301) 796-6707 I (866) 405-5367